false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - The Car ...
The Overlooked Organ: Integrating Liver Disease in ...
The Overlooked Organ: Integrating Liver Disease into the CKM Framework
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Professor Arun Sanyal argues that metabolic dysfunction-associated steatotic liver disease (MASLD) should be considered alongside cardiovascular and kidney disease as part of interconnected metabolic health. Driven largely by diet-related obesity and insulin resistance, MASLD can progress from liver fat to inflammation, fibrosis, cirrhosis, and liver cancer. It also increases risks of type 2 diabetes, hypertension, cardiovascular events, and chronic kidney disease; combined liver scarring and CKD are associated with higher mortality.<br /><br />Sanyal distinguishes disease activity (ongoing liver injury) from disease stage (fibrosis). He recommends assessing liver risk with the FIB-4 score, calculated from routine blood tests. A score below 1.3 generally indicates low immediate liver risk; above 2.6 warrants specialist evaluation. Intermediate or elevated results may require transient elastography (FibroScan), with liver stiffness above 10 suggesting increased risk and values above 20 raising concern for advanced disease.<br /><br />He advocates replacing organ-by-organ care with integrated metabolic assessment, including attention to nutrition, physical activity, sleep, mental health, and comorbidities. GLP-1 medications, including semaglutide, show promise for MASH; resmetirom is another approved treatment for patients with fibrosis. In discussion, he notes that ultrasound can detect liver fat but is less useful for prognosis, while FIB-4 is broadly validated.
Asset Caption
Arun J. Sanyal, MD, MBBS
Meta Tag
Speaker
Arun J. Sanyal
Keywords
MASLD
metabolic health
FIB-4 score
fibrosis
transient elastography
GLP-1 medications
resmetirom
×
Please select your language
1
English